Latest:
Ponatinib Continues March to Potential Front-line Use in CML
PACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David Hyman, MD
Latest:
Dr. Hyman on MEDI3617 as Potential Treatment for Patients with Advanced Solid Tumors
David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective angiopoietin-2 inhibitor MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.
David I. Quinn, MBBS, PhD
Latest:
Dr. Quinn on Targetable Molecular Pathways in RCC
David I. Quinn, MBBS, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, USC Keck School of Medicine, discusses targetable molecular pathways in renal cell carcinoma.
David I. Quinn, MD, MBBS, PhD, FRACP, FACP
Latest:
Dr. Quinn on Novel Hormonal Therapies in Prostate Cancer
David I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the rise of novel hormonal therapies in prostate cancer.
David I. Quinn, MD, PhD
Latest:
Dr. Quinn on Current State of Biomarkers in RCC
David I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.
David J. Andorsky, MD
David J. Andorsky, MD, is a medical oncologist and hematologist at Rocky Mountain Cancer Centers; as well as the associate chair of US Oncology Hematology Research.
Latest:
Dr Andorsky on Molecular Responses With Second-Line Asciminib in CP-CML
David J. Andorsky, MD, discusses molecular responses achieved with asciminib dose escalation in patients with CP-CML who had received 1 prior TKI.
David J. Einstein, MD
Latest:
Dr. Einstein on Treatment Approaches in Early Oligometastatic Prostate Cancer
David J. Einstein, MD, instructor of medicine, Harvard Medical School, attending physician, Beth Israel Deaconess Medical Center, discusses treatment approaches for patients with early evidence of oligometastatic prostate cancer.
David J. Straus, MD
Latest:
Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin Lymphoma
David J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.
David Korones, MD
Latest:
(Never) A Typical Day in the Life of a Pediatric Hematologist/Oncologist
There is no such thing as a typical day. Our days are punctuated by the unexpected and our field is so diverse that we often change what we do over the course of our careers. Time alters us and our field.
